Compare Amphastar Pharmaceuticals Inc (AMPH) vs Deere & Company (DE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Deere & Company — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Deere & Company trades at $586.86 (market cap $158.42B). The key difference: Deere & Company is far larger — about 191.8× Amphastar Pharmaceuticals Inc's market cap, and Deere & Company pays a 1.1% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DE | |
|---|---|---|
Market Cap | $826.08M | $158.42B |
Sector | Health | Industrials |
52-Week High | $30.81 | $662.49 |
52-Week Low | $16.87 | $439.11 |
Enterprise Value | $1.22B | $213.24B |
Dividend Yield | — | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Deere & Company (DE) trades at $586.86, down 1.02% on the day, near the lower end of its 52-week range. The stock shows a bullish technical signal with recent earnings beats but faces revenue declines from $60.2B in 2023 to $44.7B in 2025. Analyst consensus is mixed with a $689.30 price target, and the company maintains strong cash flow from operations of $7.46B in 2025.
The outlook hinges on agricultural sector recovery and precision farming growth, offering potential upside if earnings stabilize. Risks include cyclical demand, high debt levels, and margin pressure from declining net income. Investor sentiment is cautious amid volatile farm economics, yet institutional holdings suggest long-term confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
